Log In
Print this Print this

omarigliptin (Marizev) (MK-3102)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionOnce-weekly, oral dipeptidyl peptidase-4 (DPP-4; CD26) inhibitor
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today